Breaking News on Contract Research, Manufacturing & Clinical Trials

Asian CRO bags new diabetes contract

By Kirsty Barnes, 25-May-2006

Related topics: Phase III-IV, Clinical Development

US biotech company Spherix has selected Singapore-based clinical research organisation (CRO) Gleneagles to take charge of the Phase III clinical trial program for its new Type 2 diabetes drug, Naturlose.

Gleneagles is a subsidiary of Asia's largest health-care provider, Parkway Hospital Singapore, whose network includes 12 hospitals in Australia, where the bulk of the Phase III trial will be conducted.

Patient recruitment is tipped to start by the end of the year.

 

Gleneagles has a good record for participating in US Food and Drug Administration (FDA) approved clinical trials, Spherix said in a statement.

 

"We chose Gleneagles because they have the track record, the resources and the stature needed to conduct the Phase III trial in a way that maximises both the efficiency and the scientific validity of this kind of complex process," said Spherix president and CEO Richard Levin.

 

Previous clinical trials of Naturlose have indicated that the drug can blunt the glucose spikes that occur after meals, and may be useful in controlling certain symptoms of type 2 diabetes, said the firm.

 

Diabetes now affects more than 18m people in the US alone and 170m people worldwide. Type 2 diabetes is the most common form of the disease.

 

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.